Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ExPlas
- Development stage
- Phase 2
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
ExPlas is an investigational blood product, specifically 'exercised blood plasma', currently being evaluated in a clinical trial for patients with early symptomatic Alzheimer's disease. The treatment involves infusions of ExPlas, with the hypothesis that it may improve cognitive function or slow disease progression by 'thinning out' a 'poor' signaling environment in the blood. The ongoing study is a randomized, double-blinded trial comparing ExPlas to commercial blood plasma (Octaplasma) and saline (placebo).
- Other names
- exercised plasmaExPlas
Beyond the preview
Go deeper on ExPlas.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ExPlas.